{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:44Z","timestamp":1791207344612,"version":"4.1.0"},"reference-count":54,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"The authors have no funding to report"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2023,4,3]]},"DOI":"10.1080\/14737140.2023.2192930","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T05:06:00Z","timestamp":1679029560000},"page":"351-359","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Pemigatinib for the treatment of myeloid\/lymphoid neoplasms with <i>FGFR1<\/i> rearrangement"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-8134","authenticated-orcid":false,"given":"Craig W.","family":"Freyer","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Department of Medicine, Division of Hematology\/Oncology, Perelman School of Medicine and the Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6572-1077","authenticated-orcid":false,"given":"Mitchell E.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"},{"name":"Lymphoma Program, Hematology\/Oncology Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3028-1662","authenticated-orcid":false,"given":"Alison","family":"Carulli","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bagg","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Perelman School of Medicine and the Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1397663"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.11.003"},{"issue":"10","key":"cit0005","first-page":"1628","volume":"9","author":"Macdonald D","year":"1995","journal-title":"Leukemia"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02451-y"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2007.04.007"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1446279"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1159\/000046639"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-695973"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000368"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162320"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148103"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01553-x"},{"key":"cit0015","unstructured":"Pemazyre [package insert]. Wilmington, DE: Incyte Corporation; 2022."},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.05.013"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.001"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163099"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy173"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122968"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2015.9"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00305-9"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1177\/2474126417751724"},{"key":"cit0025","unstructured":"National Association of Specialty Pharmacy. NASP definitions of specialty pharmacy and specialty medications. Website: NASPNET.org. Published February 24, 2016. [Cited 2023 Jan 11]. https:\/\/naspnet.org\/wp-content\/uploads\/2017\/02\/NASP-Defintions-final-2.16.pdf"},{"key":"cit0026","unstructured":"Incyte Corporation. Pemazyre healthcare professionals website. 2022. [Cited 2023 Jan 11]. https:\/\/hcp.pemazyre.com"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211072467"},{"key":"cit0028","unstructured":"European Medicines Agency. Pemazyre. Last updated January 9, 2023. [Cited 2023 Jan 14]. https:\/\/www.ema.europa.eu\/en\/medicines.human\/EPAR\/pemazyre"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1838484"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01157-0"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0115-y"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30848"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03098-1"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0124-y"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01628-3"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.066407"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.188"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.8"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12957"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.136"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2812.2812"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404438101"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.05.013"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2013.04.001"},{"key":"cit0045","unstructured":"Futibatinib in Patients With Specific FGFR Aberrations. Clinicaltrials.gov identifier: NCT04189445. Updated October 21, 2022. [Cited 2023 Jan 11]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04189445?cond=Futibatinib&draw=2&rank=1"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002308"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074286"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036558"},{"key":"cit0049","unstructured":"Balversa [package insert]. Horsham, PA: Janssen Products, LP; 2019."},{"key":"cit0050","unstructured":"Truseltiq [package insert]. Brisbane, CA: QED therapeutics, Inc; 2021."},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2022.104577"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0595"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202101328"},{"key":"cit0054","unstructured":"Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia. Clinicaltrials.gov identifier: NCT04659616. Updated July 12, 2022. [Cited 2023 Jan 11]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04659616?term=AML&cond=pemigatinib&draw=2&rank=1"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2023.2192930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T11:15:05Z","timestamp":1684840505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2023.2192930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"alternative-id":["10.1080\/14737140.2023.2192930"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2023.2192930","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}